(PEPG) PepGen Inc. Business Model Canvas Research

Contract research organizations are central to PepGen Inc.’s model because they handle preclinical studies, trial operations, data management, and safety reporting across its 3 clinical programs. That outsourced setup lets a small team run a wider pipeline without building a large internal clinical ops base.

• Supports multi-program execution with low fixed cost
• Speeds trial setup and safety oversight
• Fits PepGen’s outsourced clinical-stage structure

FDA and other regulators are core partners for PepGen Inc. on IND filings, protocol reviews, and trial oversight, while patient advocacy groups help reach the 300 million people worldwide living with rare diseases and support recruitment in Duchenne and myotonic dystrophy programs. These groups also improve disease education, trust, and community engagement.

• Regulators enable IND and trial approval.
• Advocates boost awareness and enrollment.
• Rare disease reach is 300 million worldwide.

PepGen Inc. runs preclinical pharmacology and toxicology work before and alongside clinical studies to test efficacy, tissue distribution, and safety; those results guide dose selection and support regulatory filings. This work also shows whether the EDO platform can improve muscle delivery, which is the core proof point for its pipeline.

• Guides dose and IND filings
• Tests muscle delivery
• Checks efficacy and safety

PepGen’s CMC, regulatory, and quality work is core to a clinical-stage biotech: it must keep GMP-ready manufacturing, stability testing, and batch documentation tight enough to support ongoing studies and later trials. Regulatory filings and quality systems are continuous work, not one-off tasks, because any change in process, data, or supply chain can affect trial readiness.

• GMP control protects trial supply.

• Stability data supports dose confidence.

• Quality systems must run nonstop.

PepGen is based in Cambridge, Massachusetts, a life-science hub with more than 1,000 biotech and pharma companies in Greater Boston and deep ties to Harvard, MIT, and nearby research hospitals. That location helps PepGen tap biotech talent, academic science, vendors, investors, and clinical partners fast.

• Access to dense biotech hiring pool
• Near top academic research centers
• Close to investors and trial partners

PepGen Inc.'s scientific team and clinical data are core assets: internal scientists and development staff keep the EDO platform moving, while early preclinical and clinical readouts guide dose, safety, and go/no-go calls. In a clinical-stage Company Name, know-how and datasets can matter more than factories, because each new result shapes trial design and capital use.

• Internal team drives platform execution
• Data shapes dose and safety choices
• Early readouts reduce trial risk

PepGen’s value proposition is multiple shots on target: one EDO delivery platform can support five programs, PGN-EDO51, PGN-EDODM1, PGN-EDO53, PGN-EDO45, and PGN-EDO44. That spreads risk away from a single molecule and gives the company several development paths from the same core science.

• 5 pipeline programs
• 1 delivery platform
• Lower single-asset risk
• More chances of clinical success

PepGen Inc. focuses on oligonucleotide therapies that modulate gene expression, not replace missing proteins, which fits exon-skipping and splice-modulation use cases in genetic muscle disease. This matches rare-disease precision medicine, where the target can be as small as 1 in 3,500 male births for Duchenne muscular dystrophy.

• Splice control, not protein replacement
• Best for exon-skipping disease biology
• Precision fit for rare muscle disorders

PepGen’s regulatory relationship is a tightly managed, ongoing dialogue with the FDA and other agencies, built around filings, safety updates, and protocol reviews for its 3 clinical-stage programs. Compliance and fast, transparent reporting matter here because each study amendment or adverse-event update can affect trial pace and capital use.

• Ongoing filings and protocol reviews
• Safety updates shape trial continuity
• Transparency supports regulator trust

For a clinical-stage biotech that reported no approved products and depends on R&D funding, this model is not optional: it is part of keeping studies active and de-risking future approvals.

PepGen Inc. keeps investor and partner ties strong with quarterly updates, SEC filings, and conference presentations, which matter for a clinical-stage biopharma with no product revenue. In 2025, this steady disclosure helped preserve trust and keep financing and licensing options open.

• Regular data drops reduce uncertainty
• Partner updates support deal talks
• Trust helps fund the pipeline

PepGen Inc. uses its corporate website and investor materials to share pipeline updates in one consistent place for investors, analysts, and potential partners. In 2025, these channels stayed the main source for clinical and corporate disclosures, including SEC filings, helping the market track progress across its limited-stage RNA therapeutics pipeline.

• One source for pipeline updates
• Used by investors and analysts
• Supports partner diligence

INDs, safety reports, and related filings are PepGen Inc.s main formal gate into clinic work; in its latest filings, the company reported cash and cash equivalents of about $121 million, which helps fund that regulatory path. Partner meetings and diligence are the other channel: they turn data into deal talks, which matters for a pre-commercial biotech with no product sales yet.

• INDs open clinical testing.
• Safety reports keep trials moving.
• Partner diligence can create value.

Clinical research hospitals and specialty centers are PepGen Inc.'s core trial sites because they handle screening, infusion, monitoring, and follow-up for rare-disease studies. This matters in a market where rare diseases affect about 300 million people worldwide, and complex exon-skipping trials need reliable site execution to move patients through safely and on schedule.

• Run screening and infusion visits
• Support close safety monitoring
• Enable rare-disease trial delivery
• Reduce site execution risk

If PepGen out-licenses programs, future biopharma partners become a key customer segment: they want differentiated delivery chemistry and rare-disease assets with global scale. That matters in markets like Duchenne muscular dystrophy, which affects about 1 in 3,500-5,000 male births, and myotonic dystrophy type 1, which affects about 1 in 8,000 people.

• Differentiated delivery chemistry
• Rare-disease pipeline access
• Global development scale
• Commercial launch capability

PepGen Inc. faces recurring regulatory and quality compliance costs for IND maintenance, safety reporting, quality systems, and trial documentation, because these are mandatory to run human studies. These costs usually rise as programs move into later-stage trials, where inspection readiness and data control become more demanding.

• IND upkeep and FDA reporting are recurring.

• Quality systems scale with each trial stage.

• Later-stage work raises compliance spend.

PepGen Inc. is still a public, clinical-stage biotech, so General and administrative plus IP costs cover finance, legal, HR, and corporate ops, plus patent filing and defense. These costs stay high before any product revenue, because headquarters, SEC reporting, and board support are fixed public-company overhead.

• G&A and IP are mostly fixed costs.

• Patent work protects future value.

• Public-company overhead stays material pre-launch.

PepGen Inc.’s future product sales are still contingent: as a clinical-stage, pre-commercial company, it has no commercial product revenue yet, and sales would only start if one or more programs win approval. In fiscal 2025, PepGen reported $0 product revenue, so this stream remains a future upside case, not a current driver.

• Clinical-stage only; no approved products
• Fiscal 2025 product sales: $0
• Revenue starts after approval

If PepGen licenses programs to larger pharma companies, it can earn royalties on net sales, creating long-tail value without funding full launch costs. In platform biotech deals, royalty rates often sit in the low-single-digit to mid-teens range, so even one partnered asset can matter if it reaches scale.

• Royalties can outlast development spend.
• No direct commercialization needed.
• Common exit path for platform biotechs.